News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) To Pay Out $105 Million To Settle U.S. Claims Of Improper Marketing


6/5/2014 7:01:48 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

British drugmaker GlaxoSmithKline Plc (GSK.L) has agreed to pay $105 million (62.7 million pounds) to settle allegations by 44 U.S. states and the District of Columbia that it promoted its medicines for unapproved uses, several states attorneys general announced on Wednesday. Glaxo was accused by the states of illegally marketing its big-selling asthma drug Advair for use by mild asthma sufferers and the antidepressants Paxil and Wellbutrin for use by children and teenagers without FDA approval. Several antidepressants have been associated with increased risk of suicide in younger patients. "GlaxoSmithKline put its business interests ahead of what was best for vulnerable patients," Illinois Attorney General Lisa Madigan said in a statement.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at SF Gate
Read at Chicago Tribune
Read at ABC News


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES